CompanyGraph
Beijing Balance Medical Technology Co., Ltd.
688198 · SSE · China
balancemed.cnFinancials as of FY2025
What stands out
- Valued far above the size of its business
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.5B, above the global median of $1.18B
- PositionGross margin is 89.4%, higher than 95% of its Medical Devices peers (median 58.7%)
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.10%Above 5Y avg (0.54%)
Annual Rate
CNY 0.80Paid annual
Payout Ratio
66.1%Moderate
Payback Period
85.7 yr
Last Ex-Dividend
May 26, 2026
The reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
10.04BCNY1.50B · vs all stocks (USD)
Trailing P/E
60.01xvs Medical Devices peers
Revenue (TTM)
625.98MCNY93.44M · vs all stocks (USD)
Profit Margin
26.53%vs Medical Devices peers
Beta
-0.0290xvs all stocks
52-Week Change
-32.90%vs all stocks
Market Capitalization
10.04BCNY1.50B · vs all stocks (USD)
Enterprise Value
9.66BCNY1.44B · vs all stocks (USD)
Trailing P/E
60.01xvs Medical Devices peers
Forward P/E
50.78xvs Medical Devices peers
Price to Sales (TTM)
15.98xvs Medical Devices peers
Price to Book (MRQ)
7.98xvs Medical Devices peers
Enterprise to Revenue
15.43xvs Medical Devices peers
Enterprise to EBITDA
51.33xvs Medical Devices peers
Gross Margin
89.43%vs Medical Devices peers
Profit Margin
26.53%vs Medical Devices peers
Operating Margin
-10.46%vs Medical Devices peers
Return on Assets (TTM)
6.37%vs Medical Devices peers
Return on Equity (TTM)
12.78%vs Medical Devices peers
Revenue (TTM)
625.98MCNY93.44M · vs all stocks (USD)
Revenue per Share (TTM)
4.56CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-25.40%vs Medical Devices peers
Gross Profit (TTM)
558.65MCNY83.39M · vs all stocks (USD)
EBITDA (TTM)
251.59MCNY37.55M · vs all stocks (USD)
Net Income (TTM)
166.06MCNY24.79M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-93.50%vs Medical Devices peers
Operating Cash Flow (TTM)
123.00MCNY18.36M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-68.61MCNY-10.24M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.8000CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
1.10%vs all stocks
5-Year Average Dividend Yield
0.54%vs all stocks
Payout Ratio
66.12%vs Medical Devices peers
Minority Interest (Equity)
-13.72MCNYFY2025 · Dec 31, 2025Revenue
620.15MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
67.09MCNYFY2025 · Dec 31, 2025Gross Profit
553.06MCNYFY2025 · Dec 31, 2025Operating Income
205.80MCNY30.72M · vs all stocks (USD)
Pre-tax Income
206.13MCNYFY2025 · Dec 31, 2025Income Tax Expense
26.45MCNYFY2025 · Dec 31, 2025Net Income
179.68MCNYFY2025 · Dec 31, 2025EBIT
207.57MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
251.59MCNYFY2025 · Dec 31, 2025Research & Development
155.33MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
103.13MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.04MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.77MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.44MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.41CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.41CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
137.28MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
137.28MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
179.68MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
13.89MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
89.47MCNYFY2025 · Dec 31, 2025Free Cash Flow
-46.73MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
39.26MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
179.68MCNYFY2025 · Dec 31, 2025Other Non-cash Items
3.47MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-75.27MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-18.42MCNYFY2025 · Dec 31, 2025Capital Expenditures
-136.20MCNYFY2025 · Dec 31, 2025Purchase of Investments
-18.00MCNYFY2025 · Dec 31, 2025Sale of Investments
11.03MCNYFY2025 · Dec 31, 2025Other Investing Activity
-35.60MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-178.76MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
75.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-110.84MCNYFY2025 · Dec 31, 2025Other Financing Charges
658.39KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-35.18MCNYFY2025 · Dec 31, 2025Shares Outstanding
137.75MSharesUpdated Sep 22, 2026Float Shares
36.42MSharesUpdated Sep 22, 2026% Held by Insiders
73.27%vs all stocks
% Held by Institutions
7.94%vs all stocks
Total Cash (MRQ)
387.78MCNY57.88M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.81CNYUpdated Sep 22, 2026Total Debt (MRQ)
59.23MCNY8.84M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0478xvs Medical Devices peers
Current Ratio (MRQ)
5.33xvs Medical Devices peers
Book Value per Share (MRQ)
9.10CNYUpdated Sep 22, 2026Total Assets
1.62BCNY242.27M · vs all stocks (USD)
Total Current Assets
903.75MCNYFY2025 · Dec 31, 2025Total Liabilities
309.83MCNYFY2025 · Dec 31, 2025Total Non-current Assets
719.29MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
82.46MCNYFY2025 · Dec 31, 2025Total Current Liabilities
227.37MCNYFY2025 · Dec 31, 2025Cash
39.26MCNYFY2025 · Dec 31, 2025Cash Equivalents
459.94KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
39.72MCNYFY2025 · Dec 31, 2025Other Short-term Investments
283.83MCNYFY2025 · Dec 31, 2025Accounts Receivable
162.06MCNYFY2025 · Dec 31, 2025Inventory
68.62MCNYFY2025 · Dec 31, 2025Accounts Payable
54.42MCNYFY2025 · Dec 31, 2025Short-term Debt
78.19MCNYFY2025 · Dec 31, 2025Other Current Liabilities
14.99KCNYFY2025 · Dec 31, 2025Long-term Debt
15.43MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
17.10MCNYFY2025 · Dec 31, 2025Common Stock (Book)
137.75MCNYFY2025 · Dec 31, 2025Retained Earnings
286.46MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.31BCNY196.02M · vs all stocks (USD)
52-Week Low
67.03CNYUpdated Sep 22, 202652-Week High
132.94CNYUpdated Sep 22, 202652-Week Change
-32.90%vs all stocks
Beta
-0.0290xvs all stocks
50-Day MA
77.33CNYUpdated Sep 22, 2026200-Day MA
93.70CNYUpdated Sep 22, 2026Avg 10-Day Volume
328.54KSharesUpdated Sep 22, 2026Avg 30-Day Volume
673.83KSharesUpdated Sep 22, 2026Diluted EPS (TTM)
1.21CNYUpdated Sep 22, 20268 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 89.4%, higher than 95% of its Medical Devices peers (median 58.7%)Significant
Gross margin: 0.89Industry median: 0.59Industry P95: 0.79Peers compared: 60.00
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 15.98Revenue Growth YoY: -0.25
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.56
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.5B, above the global median of $1.18BNotable
Market cap (USD): 1,498,328,441.941Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Tyra Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Taysha Gene Therapies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Concord Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Classys Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Taienkang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inhibrx Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Dongcheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Classys Inc.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Suzhou Shihua New Material Technology Inc.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Anhui XDLK Microsystems Co., Ltd.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity